FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017226821> ?p ?o ?g. }

• W2017226821 endingPage "989" @default.
• W2017226821 startingPage "984" @default.
• W2017226821 abstract "Objective The purpose of this study was to determine if an elevated concentration of soluble fms-like tyrosine kinase-1(sFlt-1) in maternal plasma and amniotic fluid is a risk factor for the subsequent development of preeclampsia. Study design A case-control study was conducted to compare mid-trimester concentrations of maternal plasma and amniotic fluid sFlt-1 in patients who developed preeclampsia with those who did not. The study included 32 cases with preeclampsia (18 cases: severe preeclampsia) and 128 matched controls with normal outcomes. Patients with an abnormal fetal karyotype or major anomaly, multiple pregnancies, chronic hypertension, diabetes, and renal disease were excluded. Soluble Flt-1 concentration was measured by specific immunoassay. Nonparametric techniques were used for statistical analysis. Results 1) The median maternal plasma, but not amniotic fluid, sFlt-1 concentration in patients who developed preeclampsia was significantly higher than in the control cases (maternal plasma: median 730 pg/mL, range 60-3375 pg/mL vs median 441 pg/mL, range 58-1959 pg/mL, P < .05; amniotic fluid: median 10,504 pg/mL, range 5253-38,023 pg/mL vs median 10,236 pg/mL, range 4326-87,684 pg/mL, P = .65). 2) The median plasma concentration of sFlt-1 was higher in cases of severe preeclampsia than in those with mild preeclampsia without reaching statistical significance (median 762 pg/mL, range 261-3309 pg/mL vs median 334 pg/mL, range 60-3375 pg/mL; P = .07). However, there was no significant difference in the median amniotic fluid sFlt-1 concentrations between patients with severe preeclampsia and those with mild preeclampsia (P = .45). 3) An elevated maternal plasma sFlt-1 concentration (higher than 700 pg/mL) is a risk factor for the development of preeclampsia (OR 3.9, 95% CI 1.7-8.6) and severe preeclampsia (OR 7.4, 95% CI 2.5-22.1) after genetic amniocentesis. 4) The median interval from amniocentesis to the diagnosis of preeclampsia in patients with maternal plasma sFlt-1 concentrations higher than 700 pg/mL was 117 days (range 19-154 days). Conclusion An elevated concentration of sFlt-1 in maternal plasma at the time of mid-trimester amniocentesis is a risk factor for the subsequent development of preeclampsia. The purpose of this study was to determine if an elevated concentration of soluble fms-like tyrosine kinase-1(sFlt-1) in maternal plasma and amniotic fluid is a risk factor for the subsequent development of preeclampsia. A case-control study was conducted to compare mid-trimester concentrations of maternal plasma and amniotic fluid sFlt-1 in patients who developed preeclampsia with those who did not. The study included 32 cases with preeclampsia (18 cases: severe preeclampsia) and 128 matched controls with normal outcomes. Patients with an abnormal fetal karyotype or major anomaly, multiple pregnancies, chronic hypertension, diabetes, and renal disease were excluded. Soluble Flt-1 concentration was measured by specific immunoassay. Nonparametric techniques were used for statistical analysis. 1) The median maternal plasma, but not amniotic fluid, sFlt-1 concentration in patients who developed preeclampsia was significantly higher than in the control cases (maternal plasma: median 730 pg/mL, range 60-3375 pg/mL vs median 441 pg/mL, range 58-1959 pg/mL, P < .05; amniotic fluid: median 10,504 pg/mL, range 5253-38,023 pg/mL vs median 10,236 pg/mL, range 4326-87,684 pg/mL, P = .65). 2) The median plasma concentration of sFlt-1 was higher in cases of severe preeclampsia than in those with mild preeclampsia without reaching statistical significance (median 762 pg/mL, range 261-3309 pg/mL vs median 334 pg/mL, range 60-3375 pg/mL; P = .07). However, there was no significant difference in the median amniotic fluid sFlt-1 concentrations between patients with severe preeclampsia and those with mild preeclampsia (P = .45). 3) An elevated maternal plasma sFlt-1 concentration (higher than 700 pg/mL) is a risk factor for the development of preeclampsia (OR 3.9, 95% CI 1.7-8.6) and severe preeclampsia (OR 7.4, 95% CI 2.5-22.1) after genetic amniocentesis. 4) The median interval from amniocentesis to the diagnosis of preeclampsia in patients with maternal plasma sFlt-1 concentrations higher than 700 pg/mL was 117 days (range 19-154 days). An elevated concentration of sFlt-1 in maternal plasma at the time of mid-trimester amniocentesis is a risk factor for the subsequent development of preeclampsia." @default.
• W2017226821 created "2016-06-24" @default.
• W2017226821 creator A5013562873 @default.
• W2017226821 creator A5021734388 @default.
• W2017226821 creator A5048191543 @default.
• W2017226821 creator A5066138539 @default.
• W2017226821 creator A5067511554 @default.
• W2017226821 creator A5074131210 @default.
• W2017226821 date "2005-09-01" @default.
• W2017226821 modified "2023-09-23" @default.
• W2017226821 title "An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia" @default.
• W2017226821 cites W1973680815 @default.
• W2017226821 cites W1983337962 @default.
• W2017226821 cites W1991959440 @default.
• W2017226821 cites W1993066369 @default.
• W2017226821 cites W2025961381 @default.
• W2017226821 cites W2046507292 @default.
• W2017226821 cites W2055782921 @default.
• W2017226821 cites W2084586130 @default.
• W2017226821 cites W2104732966 @default.
• W2017226821 cites W2123266930 @default.
• W2017226821 cites W2129206669 @default.
• W2017226821 cites W2143180984 @default.
• W2017226821 cites W2167528781 @default.
• W2017226821 cites W2169958477 @default.
• W2017226821 cites W3160565403 @default.
• W2017226821 cites W37710132 @default.
• W2017226821 cites W4251118184 @default.
• W2017226821 cites W4251651167 @default.
• W2017226821 cites W4293416907 @default.
• W2017226821 cites W4382916220 @default.
• W2017226821 doi "https://doi.org/10.1016/j.ajog.2005.06.033" @default.
• W2017226821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16157098" @default.
• W2017226821 hasPublicationYear "2005" @default.
• W2017226821 type Work @default.
• W2017226821 sameAs 2017226821 @default.
• W2017226821 citedByCount "84" @default.
• W2017226821 countsByYear W20172268212012 @default.
• W2017226821 countsByYear W20172268212013 @default.
• W2017226821 countsByYear W20172268212014 @default.
• W2017226821 countsByYear W20172268212015 @default.
• W2017226821 countsByYear W20172268212016 @default.
• W2017226821 countsByYear W20172268212017 @default.
• W2017226821 countsByYear W20172268212018 @default.
• W2017226821 countsByYear W20172268212019 @default.
• W2017226821 countsByYear W20172268212021 @default.
• W2017226821 countsByYear W20172268212022 @default.
• W2017226821 countsByYear W20172268212023 @default.
• W2017226821 crossrefType "journal-article" @default.
• W2017226821 hasAuthorship W2017226821A5013562873 @default.
• W2017226821 hasAuthorship W2017226821A5021734388 @default.
• W2017226821 hasAuthorship W2017226821A5048191543 @default.
• W2017226821 hasAuthorship W2017226821A5066138539 @default.
• W2017226821 hasAuthorship W2017226821A5067511554 @default.
• W2017226821 hasAuthorship W2017226821A5074131210 @default.
• W2017226821 hasConcept C126322002 @default.
• W2017226821 hasConcept C131872663 @default.
• W2017226821 hasConcept C134018914 @default.
• W2017226821 hasConcept C16685009 @default.
• W2017226821 hasConcept C172680121 @default.
• W2017226821 hasConcept C2776871010 @default.
• W2017226821 hasConcept C2777218350 @default.
• W2017226821 hasConcept C2777966818 @default.
• W2017226821 hasConcept C2778194526 @default.
• W2017226821 hasConcept C2778258057 @default.
• W2017226821 hasConcept C2779184299 @default.
• W2017226821 hasConcept C2779234561 @default.
• W2017226821 hasConcept C54355233 @default.
• W2017226821 hasConcept C71924100 @default.
• W2017226821 hasConcept C86803240 @default.
• W2017226821 hasConcept C90924648 @default.
• W2017226821 hasConceptScore W2017226821C126322002 @default.
• W2017226821 hasConceptScore W2017226821C131872663 @default.
• W2017226821 hasConceptScore W2017226821C134018914 @default.
• W2017226821 hasConceptScore W2017226821C16685009 @default.
• W2017226821 hasConceptScore W2017226821C172680121 @default.
• W2017226821 hasConceptScore W2017226821C2776871010 @default.
• W2017226821 hasConceptScore W2017226821C2777218350 @default.
• W2017226821 hasConceptScore W2017226821C2777966818 @default.
• W2017226821 hasConceptScore W2017226821C2778194526 @default.
• W2017226821 hasConceptScore W2017226821C2778258057 @default.
• W2017226821 hasConceptScore W2017226821C2779184299 @default.
• W2017226821 hasConceptScore W2017226821C2779234561 @default.
• W2017226821 hasConceptScore W2017226821C54355233 @default.
• W2017226821 hasConceptScore W2017226821C71924100 @default.
• W2017226821 hasConceptScore W2017226821C86803240 @default.
• W2017226821 hasConceptScore W2017226821C90924648 @default.
• W2017226821 hasIssue "3" @default.
• W2017226821 hasLocation W20172268211 @default.
• W2017226821 hasLocation W20172268212 @default.
• W2017226821 hasOpenAccess W2017226821 @default.
• W2017226821 hasPrimaryLocation W20172268211 @default.
• W2017226821 hasRelatedWork W1897969001 @default.
• W2017226821 hasRelatedWork W1993795923 @default.
• W2017226821 hasRelatedWork W2017226821 @default.
• W2017226821 hasRelatedWork W2036906520 @default.
• W2017226821 hasRelatedWork W2093187320 @default.
• W2017226821 hasRelatedWork W2098357837 @default.

• next